Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6552 PK study with Modafinil in healthy males
NCT06665230Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-6552 in narcolepsy, sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 1 month, Number of Participants Who Discontinue Study Treatment Due to an AE at 19 days and 4 more. Started Sep 2023; status: completed.
02
Drugs
MK-6552
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT06665230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665230.